Skye Bioscience, Inc. Common Stock (SKYE) Stock Price

SKYEStock

$1.77−93.62%52W

Market Cap$7.86M

P/E—

PEG Ratio—

Div yield—

Beta2.84

SKYE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-81.85%

Price vs S&P 500 (4W)-63.53%

VGM Score4.95

Book Value / Share (Quarterly)$0.26

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.21

Price vs S&P 500 (YTD)-83.24%

Gross Margin (TTM)39.29%

Net Profit Margin (TTM)-3.57%

EPS (TTM)$-1.45

10-Day Avg Trading Volume0.24M

EPS Excl Extra (TTM)$-1.45

EPS (Annual)$-1.41

ROI (Annual)-279.29%

Gross Margin (Annual)35.29%

Cash / Share (Quarterly)$0.49

ROA (Last FY)-197.52%

EBITD / Share (TTM)$-1.47

ROE (5Y Avg)-346.11%

Operating Margin (TTM)-7.14%

Cash Flow / Share (Annual)$-1.29

P/B Ratio2.11x

P/B Ratio (Quarterly)2.28x

Net Income / Employee (Annual)$-4,660,400

Net Interest Coverage (TTM)-45.68x

ROA (TTM)-162.39%

EPS Incl Extra (Annual)$-1.41

Current Ratio (Annual)3.30x

Quick Ratio (Quarterly)1.67x

3-Month Avg Trading Volume0.05M

52-Week Price Return-93.62%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.14

P/S Ratio (Annual)55.92x

Asset Turnover (Annual)2.27x

52-Week High$39.92

EPS Excl Extra (Annual)$-1.41

CapEx CAGR (5Y)-8.80%

26-Week Price Return-69.92%

Quick Ratio (Annual)3.24x

13-Week Price Return-73.90%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.78x

Enterprise Value$10.91M

Asset Turnover (TTM)1.93x

Book Value / Share Growth (5Y)-36.64%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)0.00%

Cash / Share (Annual)$0.80

3-Month Return Std Dev82.86%

Net Income / Employee (TTM)$-4,777,600

ROE (Last FY)-279.29%

Net Interest Coverage (Annual)-44.71x

EPS Basic Excl Extra (Annual)$-1.41

Receivables Turnover (TTM)9.33x

Total Debt / Equity (Quarterly)0.03x

EPS Incl Extra (TTM)$-1.45

ROI (TTM)-216.75%

P/S Ratio (TTM)67.90x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$-0.82

Price vs S&P 500 (52W)-112.18%

Year-to-Date Return-70.42%

5-Day Price Return-18.20%

EPS Normalized (Annual)$-1.41

ROA (5Y Avg)-169.91%

Net Profit Margin (Annual)0.00%

Month-to-Date Return-60.99%

Cash Flow / Share (TTM)$-9.31

EBITD / Share (Annual)$-1.45

Operating Margin (Annual)0.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-130.36%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.45

P/TBV (Quarterly)11.06x

P/B Ratio (Annual)1.20x

Pretax Margin (TTM)-3.57%

Book Value / Share (Annual)$0.60

Price vs S&P 500 (13W)-75.85%

Beta2.84x

Revenue / Share (TTM)$0.00

ROE (TTM)-217.27%

52-Week Low$1.76

mGradeF

vgmGradeF

SKYE Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 14, 2026	-$2.11	-$1.55	+26.19%(+$0.55)
Q1 2026	May 11, 2026	-$2.59	-$2.56	+1.03%(+$0.03)
Q4 2025	Mar 10, 2026	-$2.45	-$2.95	-20.20%(-$0.50)
Q3 2025	Nov 10, 2025	-$2.56	-$2.59	-1.22%(-$0.03)
Q2 2025	Aug 7, 2025	-$0.30	-$0.45	-48.90%(-$0.15)

SKYE Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.07

4.00

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
SKYESkye Bioscience, Inc. Common Stock	—	—	F	$1.77
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Skye Bioscience, Inc. Common Stock

Skye Bioscience is a San Diego-based pharmaceutical company developing CB1 receptor-targeted therapies for metabolic and inflammatory disorders. Lead candidates in Phase 2 are nimacimab for obesity and SBI-100 Ophthalmic Emulsion for glaucoma and ocular hypertension. The platform also targets fibrotic and neurodegenerative diseases.